Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.
Cushing's disease is the result of chronic overproduction of ACTH by a pituitary tumor. Although the optimal treatment is surgical removal of the adenoma, medical treatment might be an option in selected cases. A 40-year old woman with Cushing's disease was treated with cabergoline, a neuromodulatory drug, for a corticotrophic macroadenoma. Treatment was initiated at a weekly dose of 0.5 mg and then, on the basis of the evolution of UFC values, adjusted until it reached 6 mg/week. With cabergoline treatment the patient was asymptomatic, the pituitary adenoma showed a significant shrinkage on MRI and urinary cortisol excretion remained within the normal range during 7 years. We show the effectiveness of cabergoline in maintaining long-term biochemical control of hypercortisolism with significant reduction and stabilization of macroadenoma volume in a patient with Cushing's disease.
Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina. mmanavela@gmail.com
Marcos Paulo
MP
Manavela
K
K
Danilowicz
O D
OD
Bruno
D000328:Adult; D000077465:Cabergoline; D003480:Cushing Syndrome / Q000188:drug therapy; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy
D004873:Ergolines; D000077465:Cabergoline